Legend Biotech Corp - Asset Resilience Ratio
Legend Biotech Corp (LEGN) has an Asset Resilience Ratio of 11.79% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Legend Biotech Corp's Asset Resilience Ratio has changed over time. Check LEGN strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Legend Biotech Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Legend Biotech Corp market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $188.21 Million | 11.79% |
| Total Liquid Assets | $188.21 Million | 11.79% |
Asset Resilience Insights
- Moderate Liquidity: Legend Biotech Corp has 11.79% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Legend Biotech Corp Industry Peers by Asset Resilience Ratio
Compare Legend Biotech Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
Jinyu Bio-Technology Co Ltd
SHG:600201 |
Biotechnology | 1.20% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
Annual Asset Resilience Ratio for Legend Biotech Corp (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Legend Biotech Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.69% | $46.70 Million | $1.73 Billion | -47.36pp |
| 2024-12-31 | 50.05% | $835.93 Million | $1.67 Billion | +48.37pp |
| 2023-12-31 | 1.68% | $31.00 Million | $1.85 Billion | -16.33pp |
| 2022-12-31 | 18.00% | $239.62 Million | $1.33 Billion | +0.72pp |
| 2021-12-31 | 17.28% | $193.46 Million | $1.12 Billion | +10.36pp |
| 2020-12-31 | 6.92% | $50.00 Million | $722.09 Million | -19.34pp |
| 2019-12-31 | 26.26% | $75.56 Million | $287.71 Million | +24.86pp |
| 2018-12-31 | 1.40% | $6.01 Million | $429.05 Million | -- |
About Legend Biotech Corp
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of mult… Read more